Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301470 | 0.93 | SCN9A (0.46) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12314715 | 0.92 | SCN9A (0.45) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL385415 | 0.89 | SCN9A (0.45) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10185978 | 0.88 | SCN9A (0.58) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329133 | 0.84 | SCN9A (0.49) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL13962804 | 0.84 | SCN9A (0.45) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3328935 | 0.82 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3333654 | 0.81 | SCN9A (0.43) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL484121 | 0.81 | SCN9A (0.45) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2308990 | 0.81 | SCN9A (0.61) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101647-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | claimed |
| EP-2350091-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| EP-2350091-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| US-8101647-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110112162-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-12 | — | — | US | disclosed |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-04-22 | — | — | US | disclosed |
| WO-2010045197-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112162-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
| US-20100099728-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.